Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
Topical formulation of paromomycin ATI-1801 already shown to be safe and effective against the disfiguring disease in Phase 3 study ATI-1801 may be eligible for tropical disease priority review vouch...